Court rules against Pfizer in religious discrimination suit

A New Jersey appeals court has ruled that a former Pfizer employee didn't agree to waive her rights to sue the company over alleged religious discrimination

Walmart pharmacies to stop being part of CVS Health’s prescription drug network

Walmart Inc. pharmacies will no longer be part of the networks where most consumers with CVS Health Corp. drug plans can pick up their prescriptions, after a dispute between the two giant companies over pricing.

Walmart pharmacies to stop being part of CVS Health’s prescription drug network

Walmart Inc. pharmacies will no longer be part of the networks where most consumers with CVS Health Corp. drug plans can pick up their prescriptions, after a dispute between the two giant companies over pricing.

These two Philly medical stocks doubled investors’ money in 2018

Tabula Rasa Healthcare, the Moorestown-based drug-delivery software firm, and BioTelemetry, the Malvern heart-monitor maker, ranked among the top 10 for share-price gains among the Standard & Poor’s index of 600 small-cap stocks in 2018.

These two Philly medical stocks doubled investors’ money in 2018

Tabula Rasa Healthcare, the Moorestown-based drug-delivery software firm, and BioTelemetry, the Malvern heart-monitor maker, ranked among the top 10 for share-price gains among the Standard & Poor’s index of 600 small-cap stocks in 2018.

AstraZeneca hires former Sloan Kettering chief who failed to disclose industry payments

In hiring Jose Baselga, Astra saw the chance to bring on one of the top minds in cancer and is willing to weather criticism that he failed to disclose millions in financial support from the industry in his journal articles.

AstraZeneca hires former Sloan Kettering chief who failed to disclose industry payments

In hiring Jose Baselga, Astra saw the chance to bring on one of the top minds in cancer and is willing to weather criticism that he failed to disclose millions in financial support from the industry in his journal articles.
More Stories
Column

Double deals: eLocal buys two call firms; OraSure adds biome, urine testers

Area tech and biotech companies who specialize in finding out all your personal information each announce two acquisitions

Column

University of Pennsylvania professor’s gene-therapy start-up raises another $50 million

The startup, which specializes in developing drugs to treat autoimmune diseases including lupus and multiple sclerosis with a new type of gene therapy, had previously raised $38 million.

Former Flyers enforcer, cannabis advocates prepare for the Pa. hemp industry to rocket after Trump’s approval of Farm Bill

Industrial hemp, the non-psychoactive sister of the marijuana plant, is set to take off next year as a cash crop.

Reuters: J&J knew for decades that asbestos lurked in its baby powder

An investigation found that Johnson & Johnson's Baby Powder was sometimes tainted with asbestos, a fact the New Jersey company kept from the public for decades.

A cannabis futurist foresees dirt-cheap weed, THC appetizers, and a big impact from Canada

This Carnegie Mellon University professor predicts the cost of marijuana will fall to near zero and that joints could be given away like chocolates on a hotel pillow. He worries that usage could then explode especially among the poor.

Pa. auditor general wants to take a whack at firms that negotiate drug benefits for the Medicaid program

Pennsylvania Auditor General Eugene DePasquale wants the state to better manage an entire layer of the Medicaid program -- the pharmacy benefit managers -- who have made millions from the program.

J&J, BioMotiv invest $13M in Philly’s Aro Biotherapeutics and its Centyrin protein cancer drugs

The company, based at the University of Pennsylvania’s Pennovation Center, is trying to develop therapies for "undruggable disease."

Probe of generic ‘cartel’ grows to 300 drugs

What started as an antitrust lawsuit brought by states over just two drugs in 2016 has exploded into an investigation of alleged price-fixing involving at least 16 companies and 300 drugs.

XyloCor raises $17 million to grow heart arteries in Philly gene-therapy deal

XyloCor’s treatment seeks to grow new coronary artery tissue to help patients with severe chest pain (angina) who can’t be treated by surgery.

Percocet maker Endo details how it manages risks from selling opioids

The company disclosed measures it put in place this year to recoup incentive pay from executives.

Merck CEO Ken Frazier rose from humble beginnings in North Philly to run a big pharma company | Industry Icons

After Ken Frazier's 8 years as CEO, the board recently extended his contract. He heads a storied research company but faces challenges especially on drug pricing.

Why Glaxo isn’t meeting with Mayor Kenney while he’s in London

GSK declined the meeting with Mayor Kenney after a City Council bill was submitted that would force drugmakers to register their sales reps. Is there a connection?

Pharmacy benefit managers testify about prescription drugs at Pa. Senate committee hearing

The companies that negotiate drug prices answered pointed questions about costs and where the money is going.

SPECIAL REPORTS
Investigative reports, featured series, and guides to living in the Philadelphia region, brought to you by The Inquirer.
WHAT ARE YOU CURIOUS ABOUT?
Send us your burning questions, or vote on other readers' questions that pique your interest. Our journalists will work to answer them.